ARK Genomic Revolution ETF
ARKG
18 hedge funds and large institutions have $7.86M invested in ARK Genomic Revolution ETF in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
38% more funds holding
Funds holding: 13 → 18 (+5)
13% more capital invested
Capital invested by funds: $6.96M → $7.86M (+$903K)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
3.97% less ownership
Funds ownership: 18.78% → 14.81% (-4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.41M |
| 2 |
MIAN
Mariner Independent Advisor Network
Overland Park,
Kansas
|
+$557K |
| 3 |
CFA
Carroll Financial Associates
Charlotte,
North Carolina
|
+$303K |
| 4 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$70.1K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$46.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$769K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$243K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$50.3K |
| 4 |
LPL Financial
San Diego,
California
|
-$32.3K |
| 5 |
IA
IFP Advisors
Tampa,
Florida
|
-$6K |
ARKG Hedge Fund Activity: Q4 2017 in Review
18 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2017, worth a combined $7.86M — up 13% from $6.96M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARKG positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $1.41M. The largest seller was Jane Street, cutting an estimated $769K.
- 18 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2017, up from 13 in Q3 2017.
- Funds reported $7.86M of ARK Genomic Revolution ETF stock for Q4 2017, up 13% quarter-over-quarter.
- 6 funds opened new ARK Genomic Revolution ETF positions in Q4 2017 and 1 closed out, a net change of +5 holders.
- The largest ARK Genomic Revolution ETF buyer in Q4 2017 was Morgan Stanley, an estimated $1.41M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2017 was Jane Street, an estimated $769K sold.
Based on aggregated 13F filings for Q4 2017.